Renal Cell Carcinoma: Causes, Symptoms, Treatment and Prognosis — Overview, Diagnosis & Treatment Options | MyMedicPlus

Renal cell carcinoma (RCC) arises from the epithelial cells of the renal tubules and accounts for approximately 90% of kidney cancers, with about 431,000 new cases diagnosed globally per year. Clear cell RCC (ccRCC) is the most common histological subtype, representing approximately 70-75% of cases; papillary RCC (Types 1 and 2) accounts for 15-20%; chromophobe RCC for approximately 5%; and rare subtypes including collecting duct carcinoma, translocation RCC, and medullary carcinoma are distinct entities with unique biology and management. The male-to-female ratio is approximately 2:1. Incidence has risen over recent decades due to incidental detection of small renal masses on cross-sectional imaging performed for other indications. The molecular hallmark of ccRCC is VHL (von Hippel-Lindau) gene inactivation — whether through germline mutation (VHL syndrome), somatic mutation, or promoter methylation — which stabilizes HIF-alpha transcription factors and drives VEGF and PDGF-mediated angiogenesis. This molecular mechanism underlies the susceptibility of ccRCC to VEGF/VEGFR-targeted therapies.

Tobacco smoking approximately doubles the risk of RCC and is the most important modifiable risk factor. Obesity, hypertension, and chronic kidney disease are established additional risk factors, with each increasing risk by approximately 1.5-2 fold. Occupational exposures to trichloroethylene (industrial solvent) and cadmium are recognized carcinogens for RCC. Hereditary syndromes collectively account for approximately 3-5% of RCC: VHL syndrome (germline VHL mutations) is the most common, causing bilateral multifocal ccRCC combined with hemangioblastomas and pheochromocytoma; hereditary papillary RCC (germline MET mutations, Type 1 papillary RCC); Birt-Hogg-Dube syndrome (germline FLCN mutations, chromophobe and hybrid oncocytic RCC with fibrofolliculomas and pneumothorax); hereditary leiomyomatosis and RCC syndrome (germline FH mutations, aggressive Type 2 papillary RCC with uterine and cutaneous leiomyomas); and BAP1 tumor predisposition syndrome. Somatic alterations in PBRM1, SETD2, BAP1, and KDM5C are common in ccRCC beyond VHL loss and influence prognosis and treatment sensitivity.

The classic triad of hematuria, flank pain, and palpable abdominal or flank mass was historically considered pathognomonic for RCC but is now present in fewer than 10% of patients — its presence usually indicates advanced or large tumors. The majority of RCC is now discovered incidentally on ultrasound or CT performed for unrelated abdominal complaints, representing a paradigm shift toward small, localized, and potentially curable disease. Hematuria (gross or microscopic) remains the most common single presenting symptom when one is present. Paraneoplastic syndromes are particularly associated with RCC: polycythemia (from ectopic EPO production), hypercalcemia (from PTHrP or 1,25-dihydroxyvitamin D production), hypertension (from renin secretion), and Stauffer syndrome (non-metastatic reversible hepatic dysfunction with elevated alkaline phosphatase). Constitutional symptoms — weight loss, fatigue, low-grade fever, and night sweats — occur in locally advanced or metastatic disease. Bone metastases cause pain or pathological fractures; pulmonary metastases are often asymptomatic until extensive.

Multiphasic contrast-enhanced CT urography (with unenhanced, arterial, nephrographic, and delayed phases) is the standard imaging study for characterization of renal masses and detection of venous extension. Renal mass biopsy (ultrasound or CT-guided core needle biopsy) is recommended for patients who are non-surgical candidates, for ambiguous lesions, and when systemic therapy rather than surgery is being considered for advanced disease — biopsy is not routinely required before surgery for typical appearing solid renal masses. MRI better characterizes venous tumor thrombus extension into the renal vein and inferior vena cava. Chest CT and bone scan (or PET/CT) detect distant metastases. IMDC (International Metastatic RCC Database Consortium) prognostic score — based on time from diagnosis to systemic therapy, Karnofsky PS, hemoglobin, calcium, neutrophils, platelets — stratifies patients into favorable, intermediate, and poor risk groups for first-line systemic therapy selection. Germline genetic testing for VHL, MET, FLCN, FH, and SDHB should be offered to patients with features suggesting hereditary RCC (young age, bilateral/multifocal, family history, associated extra-renal manifestations).

Localized RCC (T1-T2) is primarily managed surgically. Partial nephrectomy (nephron-sparing surgery) is preferred for all T1 and selected T2 tumors when technically feasible, regardless of surgical approach (open, laparoscopic, or robotic-assisted), as it preserves kidney function without compromising oncological outcomes. Radical nephrectomy (with possible regional lymphadenectomy and adrenalectomy when indicated) is used for large, complex, or centrally located tumors not amenable to partial nephrectomy. Thermal ablation (radiofrequency ablation or cryotherapy) is appropriate for small T1a tumors in patients with poor surgical fitness or solitary kidney. Adjuvant pembrolizumab (one year) is approved for high-risk resected ccRCC based on the KEYNOTE-564 trial. Active surveillance is appropriate for small (less than 3 cm) incidentally discovered renal masses in elderly or comorbid patients. For metastatic ccRCC, immunotherapy-based first-line doublets are standard: nivolumab plus ipilimumab (preferred for intermediate/poor IMDC risk); pembrolizumab plus axitinib; and lenvatinib plus pembrolizumab (the CLEAR trial showing the highest ORR). Belzutifan (HIF-2alpha inhibitor) is approved for VHL disease-associated RCC and as a third-line option for ccRCC. Second-line options: cabozantinib (CABOSUN), nivolumab (CheckMate 025), everolimus, or axitinib. Cytoreductive nephrectomy for selected patients with synchronous metastatic disease and resectable primary tumor.

The most impactful preventive measures for RCC are modifiable risk factor modification: complete tobacco cessation, weight management to achieve and maintain healthy BMI, blood pressure control (hypertension treatment), and avoidance of occupational trichloroethylene exposure. These interventions reduce risk of both RCC development and renal function decline in RCC survivors. No population-level RCC screening program exists. High-risk individuals with hereditary RCC syndromes — particularly VHL syndrome, Birt-Hogg-Dube syndrome, and hereditary papillary RCC — should undergo regular surveillance imaging (annual ultrasound or MRI from early adulthood, or from the age of 10 for VHL). Patients with any hereditary syndrome after nephrectomy for RCC require regular contralateral kidney surveillance. Newly diagnosed patients with clear cell RCC presenting at young age (under 50), bilateral or multifocal tumors, or associated extra-renal manifestations should be offered germline genetic testing and counseling.

Visible blood in the urine (gross hematuria) — particularly if painless and without urinary tract infection — should prompt same-week urology referral including upper tract evaluation with CT urography. Persistent flank or back pain on one side not attributable to musculoskeletal causes requires abdominal imaging. An incidentally discovered renal mass of any size on any imaging modality should be referred to a urologist for further characterization with CT or MRI. Any individual with known VHL syndrome, Birt-Hogg-Dube, hereditary papillary RCC, or another hereditary RCC syndrome should maintain regular scheduled surveillance with a urologist familiar with hereditary kidney cancers. Unexplained weight loss, constitutional symptoms, hypercalcemia identified on routine blood work, or an unexplained rise in hemoglobin (polycythemia) in a patient over 45 should prompt consideration of RCC among other diagnoses. Patients with a renal mass discovered at a non-specialist center should be evaluated at a tertiary center with dedicated urologic oncology expertise for management planning.

Stage I: 5-year survival over 90%. Stage II: approximately 75%. Stage III: approximately 53%. Stage IV: approximately 12-20% (dramatically improved from less than 5% historically). Modern IO/TKI doublets have transformed metastatic RCC outcomes, with sustained objective responses in favorable-risk patients and meaningful long-term survival in some patients. Belzutifan and ongoing trials continue to expand therapeutic options. The prognosis for Renal Cell Carcinoma: Causes, Symptoms, Treatment and Prognosis varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.